Evidence map›Paper›PMID 39895498›Full record

ArticleEuropean heart journal. Cardiovascular pharmacotherapy2025

Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study.

Takahiro Jimba, Hidehiro Kaneko, Yuta Suzuki, Akira Okada, Tatsuhiko Azegami, Toshiyuki Ko, Katsuhito Fujiu, Hiroyuki Morita, Norifumi Takeda, Kaori Hayashi and 6 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal. Cardiovascular pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Antiproteinuric effect of SGLT2 inhibitors in non-diabetic glomerulopathies is dependent on body mass index.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Observational
  3. SGLT2 inhibitors in CKD: are they really effective in all patients?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Review
  4. Article
  5. Role of obesity in chronic kidney disease progression.Current research in physiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Takahiro JimbaDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.ORCID 0000-0002-3757-3959
Hidehiro KanekoDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.ORCID 0000-0003-2553-6170
Yuta SuzukiDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.
Akira OkadaDepartment of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo 113-0013, Japan.
Tatsuhiko AzegamiDivision of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-0016, Japan.
Toshiyuki KoDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.
Katsuhito FujiuDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.
Hiroyuki MoritaDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.
Norifumi TakedaDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.
Kaori HayashiDivision of Endocrinology, Metabolism, and Nephrology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-0016, Japan.
Takashi YokooDivision of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo 105-8461, Japan.
Koichi NodeDepartment of Cardiovascular Medicine, Saga University, Saga 840-8502, Japan.ORCID 0000-0002-2534-0939
Issei KomuroDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.ORCID 0000-0002-0714-7182
Hideo YasunagaDepartment of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo 113-0013, Japan.
Masaomi NangakuDivision of Nephrology and Endocrinology, The University of Tokyo Graduate School of Medicine, Tokyo 113-0013, Japan.ORCID 0000-0001-7401-2934
Norihiko TakedaDepartment of Cardiovascular Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo City, Tokyo 113-0033, Japan.

Funding

Ministry of Education, Culture, Sports, Science and Technology 20H03907Ministry of Health, Labour and Welfare 23AA2003
6 · The paper itself

Abstract

aimsTo investigate the clinical significance of the modification of the kidney protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors by baseline body mass index (BMI). METHODS AND

resultsWe included individuals with SGLT2 inhibitors or dipeptidyl peptidase-4 (DPP4) inhibitors newly prescribed for type 2 diabetes using a nationwide epidemiological cohort and performed propensity score matching (1:2). The primary outcome was the annual eGFR decline, assessed using a linear mixed-effects model, compared between individuals with SGLT2 inhibitors and DPP4 inhibitors. We investigated the interaction effect of BMI at the time of prescription using a three-knot restricted cubic spline model. We analysed 2165 individuals with SGLT2 inhibitor prescriptions and 4330 individuals with DPP4 inhibitor prescriptions. Overall, the annual decline in eGFR was less pronounced in the group treated with SGLT2 inhibitors than in those treated with DPP4 inhibitors (-1.34 mL/min/1.73 m2 vs. -1.49 mL/min/1.73 m2). The advantage of SGLT2 inhibitors in mitigating eGFR decline was augmented in the individuals with higher BMI (P-value for interaction 0.0017). Furthermore, even upon adjusting the definition of outcomes to encompass a 30 or 40% reduction in eGFR, the potential advantages of SGLT2 inhibitors over DPP4 inhibitors persisted, with a trend of augmented effects with higher BMI. This interaction effect was evident in the individuals with preserved kidney function.

conclusionOur nationwide epidemiological study substantiated the improved kidney outcomes in the SGLT2 inhibitor users compared with the DPP4 inhibitor users across a wide range of BMI, which was pronounced for individuals with higher BMI.

Indexed as

Body Mass IndexDiabetes Mellitus, Type 2Diabetic NephropathiesDipeptidyl-Peptidase IV InhibitorsGlomerular Filtration RateKidneyObesitySodium-Glucose Transporter 2 InhibitorsAgedFemaleHumansMaleMiddle AgedProtective FactorsRetrospective StudiesRisk AssessmentDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2 InhibitorsBody mass indexDiabetesEstimated glomerular filtration rate declineSGLT2 inhibitor

Identifiers

PMID39895498
PMCPMC11905744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.